Greetings All:
When I consider what the pps may be before uplisting, and just considering the LYMPRO aspect and not the other catalyst; CTE/TBI plays a much larger role that should be more thoroughly considered.
I found a couple of sites that shed a very interesting light on the potential application of LYMPRO for TBI. The estimations for newly detected AD cases is about 500K per year. But, if you consider the potential of LYMPRO per TBI the facts are comparatively astonishing.
First, if you follow the link to the CDC site they offer some very astonishing facts about CTE/TBI. I am not sure if this data includes the military.
"In 2010 there were 2.5 million Emergency Room visits, hospitalizations or deaths associated with TBI-either alone or in combination with other injuries-in the United States."
http://www.cdc.gov/traumaticbraininjury/get_the_facts.html
Second, I went to the WIKI site for some background information, the article is very long and scientifically thick (it has 114 citations). But a few things stood out.
This a link to the above citations.
http://en.wikipedia.org/wiki/Chronic_traumati...phalopathy
The numbers surrounding CTE/TBI are pretty incredible. While most concussions are mild, they can still develop serious problems further on. If LYMPRO can provide function in this area it would tremendously increase the value of AMBS.
GC said he might delay the release of some LYMPRO data to the C4CT summit, perhaps because the data does indicate some function in this indication. As well, he stated he: "wanted to give the market time to digest the data". He obviously kept his powder dry, and perhaps he just doesn't want to hit the market with both barrels at once to achieve the full impact of the data! Also to give himself more latitude in choosing a partner and "leverage" in negotiations.
I personally think JN's estimates are low, it all depends on the specificity/efficacy of the results. If they are extremely high, with a couple of other anticipated catalyst: "A reverse split may not be necessary."-per GC.
LYMPRO is much further back in the pipeline for TBI, but if correlations can be drawn for it, it could be huge.
All IMHO, of course.
GLTA,
GO AMBS
When I consider what the pps may be before uplisting, and just considering the LYMPRO aspect and not the other catalyst; CTE/TBI plays a much larger role that should be more thoroughly considered.
I found a couple of sites that shed a very interesting light on the potential application of LYMPRO for TBI. The estimations for newly detected AD cases is about 500K per year. But, if you consider the potential of LYMPRO per TBI the facts are comparatively astonishing.
First, if you follow the link to the CDC site they offer some very astonishing facts about CTE/TBI. I am not sure if this data includes the military.
"In 2010 there were 2.5 million Emergency Room visits, hospitalizations or deaths associated with TBI-either alone or in combination with other injuries-in the United States."
http://www.cdc.gov/traumaticbraininjury/get_the_facts.html
Second, I went to the WIKI site for some background information, the article is very long and scientifically thick (it has 114 citations). But a few things stood out.
Quote:Chronic traumatic encephalopathy (CTE) is a form of encephalopathy that is a progressive degenerative disease, which can currently only be definitively diagnosed postmortem, in individuals with a history of multiple concussions and other forms of head injury. There has been a recent discovery[when?] of an exosome particle created by the brain which has been shown to contain trace proteins indicating the presence of the disease, however, a test is not yet available.
The sequence of events proposed by Dr. Janigro at the Cleveland Clinic links sub-concussion to leakage of the blood-brain barrier, extravasation of brain S100B in blood,[11] activation of an immune response due to antigen unmasking and production of auto-antiboides. These auto-antibodies maybe pathogenic as shown for example in epileptic human brain.[12] The link between S100B auto-antibodies and CTE needs experimental confirmation; however, antibodies against S100B or other brain protein have been found in patients affected by Alzheimer's disease.
Diagnosis[edit]
The lack of in-vivo techniques to show distinct biomarkers for CTE is the reason CTE cannot be diagnosed during lifetime. The only known diagnosis for CTE occurs by studying the brain tissue after death.
Positron Emission Tomography(PET) using a newly developed radiopharmaceutical [18F]FDDNP is being investigated as a tool to allow in-vivo diagnosis of CTE.[15] In late 2013, breaking research was completed by the University of California Los Angeles in which for the first time ever, Chronic Traumatic Encephalopathy was found in living-retired National Football League players.
At the current time PET scanning is not widely used in screening because of the high cost of the study (estimated to be $5000 USD).[18]
A putative biomarker for CTE is the presence in serum of auto-antibodies against the brain.
Nevertheless, autoimmune changes in blood of players may consist the earliest measurable event predicting CTE.
This a link to the above citations.
http://en.wikipedia.org/wiki/Chronic_traumati...phalopathy
The numbers surrounding CTE/TBI are pretty incredible. While most concussions are mild, they can still develop serious problems further on. If LYMPRO can provide function in this area it would tremendously increase the value of AMBS.
GC said he might delay the release of some LYMPRO data to the C4CT summit, perhaps because the data does indicate some function in this indication. As well, he stated he: "wanted to give the market time to digest the data". He obviously kept his powder dry, and perhaps he just doesn't want to hit the market with both barrels at once to achieve the full impact of the data! Also to give himself more latitude in choosing a partner and "leverage" in negotiations.
I personally think JN's estimates are low, it all depends on the specificity/efficacy of the results. If they are extremely high, with a couple of other anticipated catalyst: "A reverse split may not be necessary."-per GC.
LYMPRO is much further back in the pipeline for TBI, but if correlations can be drawn for it, it could be huge.
All IMHO, of course.
GLTA,
GO AMBS
